Ozempic startup Yazen raises €19.5m Series A to combat obesity (Sifted)

Swedish healthtech startup Yazen has secured a €19.5m Series A funding round, led by Evli Growth Partners and Helsana HealthInvest, to expand its digital weight-loss and diabetes treatment service across Europe. Founded in 2021, Yazen combines GLP-1 medications with lifestyle guidance, boasting over 20,000 active users and significant weight loss outcomes. With dual-certified healthcare professionals in multiple countries, Yazen minimizes expansion costs while maintaining profitability in Sweden. Although the supply of GLP-1 drugs remains limited, Yazen sees a robust market for its digital, holistic approach to obesity treatment, positioning itself as a potential unicorn in the healthtech sector.